ITRM - Iterum Therapeutics PLC

https://www.iterumtx.com

Momentum: Bearish

Recent News

Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025

GlobeNewswire • 1 month, 2 weeks ago • score: 0.03

DUBLIN, Ireland and CHICAGO, July 29, 2025 ( GLOBE NEWSWIRE ) -- Iterum Therapeutics plc ( Nasdaq: ITRM ) ( Company ) , a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, is engaged in the development of anti-infectives for multidrug resistant pathogens in Ireland and the United States. The company is headquartered in Dublin, Ireland.

52W High

$3.02

52W Low

$0.61

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

3.04

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.55

EV/Revenue (<3 favorable)

105.22

P/S (TTM) (<3 favorable)

1349.79

P/B (<3 favorable)

6.03

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.96%

Institutions (25–75% balanced)

8.58%

Shares Outstanding

44,656,900

Float

44,245,200

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

-941,000

EPS (TTM)

-0.81

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-5.56%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-1.00

Momentum

Bearish momentum

Value

-0.0349

-0.0369

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025